Methylprednisolone 500 mg powder and solvent for solution for injection/infusion, Placebo of methylprednisolone (glucose 5%), placebo of prednisone, PREDNISONE ARROW 20 mg, comprimé sécable
APHP230855
Phase 3 small_molecule active
Quick answer
Methylprednisolone 500 mg powder and solvent for solution for injection/infusion, Placebo of methylprednisolone (glucose 5%), placebo of prednisone, PREDNISONE ARROW 20 mg, comprimé sécable for Patients presenting with acute myocarditis proven by cardiac magnetic resonance imaging (CMRi) or by histological evidence on endomyocardial biopsy (EMB) is a Phase 3 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pari Pharma GmbH
- Indication
- Patients presenting with acute myocarditis proven by cardiac magnetic resonance imaging (CMRi) or by histological evidence on endomyocardial biopsy (EMB)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active